Evidence-based approaches to reducing premature cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease.

25 August 2018 (15:35 - 15:50)

Organised by:

About the speaker

Professor Darren Keith McGuire

University of Texas Southwestern Medical Center, Dallas (United States of America)

5 More presentations in this session

Welcome and introduction - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.

Professor N. Marx (Aachen, DE)

Applying evidence in practice: appropriate use of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in the cardiology clinic.

Doctor J. Udell (Toronto, CA) Professor N. Sattar (Glasgow, GB)

Advancing the standard of care in patients with type 2 diabetes and established cardiovascular disease: how can we improve patient outcomes? .

Professor N. Marx (Aachen, DE) Professor D. McGuire (Dallas, US) Doctor J. Udell (Toronto, CA) Professor S. Verma (Toronto, CA) Professor N. Sattar (Glasgow, GB)

Exploring the effects of SGLT2 inhibition in ongoing trials.

Professor S. Verma (Toronto, CA)

Summary and close - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.

Professor N. Marx (Aachen, DE)

Access the full session

Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice

The Event

ESC Congress 2018

25 August 2018 15:35 CET

You may be interested in

Congress Session

Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

27 August 2023

Congress Presentation

Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

31 August 2020

Congress Presentation

31 August 2019

Congress Presentation

Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes

1 September 2025

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

ESC 365 is supported by

Explore sponsored resources